Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Innovation Pharmaceuticals Inc

Company price
0.0002 USD 0.00(0%)
Last update at 2026-11-18T21:00:00Z
VOLUME
12600
Market Cap
2.33M

Momentum Score

…

Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.01
High
52 Week Price Range
0.00
Low
0.03
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Innovation Pharmaceuticals Inc is an OTC Pink–listed, development-stage pharmaceutical company with limited public disclosure; it appears positioned to develop novel anti-infective and anti-inflammatory therapeutics. Major long-term growth drivers may include clinical trial progress, regulatory approvals, and successful licensing or commercialization agreements, which could support increased revenue and pipeline value. Investors may find the company attractive for potential upside if programs advance and address unmet medical needs.
The most important investment risks are high probability of clinical and regulatory failure, scarce public information and low liquidity, recurring financing needs, and execution risk typical for small biopharmaceutical developers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.02M
Revenue Per Share
-
Gross Profit TTM
0.02M
Debt / Equity
-
ROE
-114.34%
Net Debt
1.34M
ROCE
-117.75%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -3.17M -7.04M -13.87M -6.65M -8.68M
Net income -3.17M -7.04M -13.87M -6.65M -8.68M
Selling general administrative 1.48M 1.96M 2.00M 2.27M 2.11M
Reconciled depreciation 0.37M 0.38M 0.38M 0.37M 0.37M
Ebit -2.94M -6.76M -9.02M -4.63M -6.30M
Ebitda - -6.54M -8.64M -6.01M -6.11M
Operating income -2.94M -6.76M -9.02M -4.63M -6.45M
Interest expense 0.06M 0.12M 4.86M 0.26M 2.20M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income - - - - 0.00M
Net interest income -0.06M -0.12M -4.86M -0.26M -2.20M
Total revenue 0.00M 0.02M 0.00M 0.42M 0.00M
Total operating expenses 2.94M 6.78M 9.02M 5.06M 6.45M
Total other income expense net -0.17M -0.17M - -1.75M -0.03M
Net income from continuing ops -3.17M -7.04M -13.87M -6.65M -8.68M
Net income applicable to common shares -3.17M -7.04M -13.87M -6.65M -8.68M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 7.52M 10.38M 14.30M 9.25M 4.05M
Intangible assets 2.00M 2.31M 2.75M 3.06M 3.34M
Other current assets 0.12M - - - -
Total liab 5.48M 5.65M 6.79M 7.79M 8.18M
Total stockholder equity 2.04M 4.73M 7.51M 1.46M -4.13M
Deferred long term liab - 0.06M 0.78M - -
Other current liab 1.49M 1.55M 1.50M 1.50M 1.49M
Common stock 0.05M 0.05M 0.04M 0.03M 0.02M
Capital stock 0.05M 0.05M 0.04M 0.03M 0.02M
Retained earnings -125.33M -122.16M -115.12M -101.24M -94.60M
Other assets 0.08M 0.14M 0.86M 0.08M 0.08M
Cash 1.52M 3.81M 10.19M 6.02M 0.58M
Total current liabilities 5.02M 4.81M 6.54M 7.37M 7.30M
Net debt - - - - 1.34M
Short term debt - - - - 1.92M
Short long term debt 0.21M 0.25M 1.46M 1.90M 1.92M
Property plant equipment - - - - 0.00M
Total current assets 1.63M 3.95M 10.69M 6.11M 0.62M
Long term investments 3.81M 3.98M - - -
Net tangible assets 0.04M 2.42M 4.75M -1.60M -7.47M
Long term debt - - - - 0.88M
Accounts payable 1.50M 1.08M 1.08M 0.56M 0.64M
Non currrent assets other - - - - 3.42M
Non current assets total 5.88M 6.43M 3.61M 3.14M 3.42M
Capital lease obligations 0.06M 0.25M 0.42M 0.56M -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.06M -4.00M -4.00M -4.00M -4.00M
Change to liabilities 0.42M 0.00M 0.52M -0.08M -1.06M
Total cashflows from investing activities -0.06M -4.08M -0.07M -0.09M -0.05M
Net borrowings -0.04M -1.03M -0.20M -0.20M -0.20M
Total cash from financing activities -0.12M 3.97M 13.74M 9.69M 4.53M
Change to operating activities -0.11M -0.38M -1.37M -0.03M -0.19M
Net income -3.17M -7.04M -13.87M -6.65M -8.68M
Change in cash -2.29M -6.39M 4.18M 5.44M -1.84M
Begin period cash flow 3.81M 10.19M 6.02M 0.58M 2.42M
End period cash flow 1.52M 3.81M 10.19M 6.02M 0.58M
Total cash from operating activities -2.11M -6.28M -9.49M -4.16M -6.33M
Issuance of capital stock - 0.00M 9.59M 0.00M 1.89M
Depreciation 0.37M 0.38M 0.38M 0.40M 0.37M
Dividends paid 0.09M 0.09M 0.09M 0.09M -
Sale purchase of stock - 0.00M -0.67M -0.06M -0.09M
Change to netincome 0.38M 0.75M 4.85M 2.21M 3.22M
Capital expenditures 0.06M 0.08M 0.07M 0.09M 0.09M
Change in working capital 0.31M -0.37M -0.85M -0.11M -1.25M
Stock based compensation 0.21M 0.58M 0.18M 0.43M 1.08M
Other non cash items - 0.18M 4.66M -0.05M 2.03M
Free cash flow -2.17M -6.36M -9.57M -4.25M -6.42M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IPIX
Innovation Pharmaceuticals Inc
-
-%
0.00 - - 409.17 1.78 202.69 -0.66
NVO
Novo Nordisk A/S
-0.54
1.36%
38.90 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-
-%
520.66 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
2.34
0.25%
923.34 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Innovation Pharmaceuticals Inc

Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.

301 Edgewater Place, Wakefield, MA, United States, 01880

978 921 4125

4

Name Title Year Born
Mr. Leo Ehrlich CPA Chairman, CEO, CFO, Principal Accounting Officer & Sec. 1958
Ms. Jane Harness M.S., MP, MS Sr. VP of Clinical Sciences & Portfolio Management 1968
Dr. W. James Alexander Consultant 1950
Mr. Jim Boeheim Bus. Advisor NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…